You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

63 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
Feb 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Dec 2020
Drug
Other Name(s): Gleevec®
Dec 2024
Drug
Other Name(s): Zydelig™
Feb 2022
Drug
Other Name(s): Besponsa®
Jul 2023
Drug
Other Name(s): Imbruvica®
Jun 2025
Drug
Other Name(s): Camptosar®
Apr 2023
Drug
Other Name(s): Ifex® (multiple brands available)
Aug 2016
Drug
Other Name(s): Idamycin®
Oct 2023

Pages